ClinicalTrials.gg
CompletedNCT06552481NP-PWD2Updated Aug 14, 2024

A Case-Control Study of Negative Pressure Platform Wound Devices (NP-PWD) for Skin and Soft Tissue Defects

An interventional study of NP-PWD and Wound Vac in Skin Wound and Soft Tissue Injuries, sponsored by The Metis Foundation. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-08-14.

Sponsored by The Metis Foundation · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was Apr 2024, 2 years 6 months ago, and no results have been posted to the registry.
  • Registered 10 months after the study started (first participant enrolled Aug 2023, registered Jul 2024).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
28
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 19 studies in Soft Tissue Injuries with a site in United States — 1 open to participants now, 1 under way, none of them phase 3. Soft Tissue Injuries · United States.

Enrollment
9th of 14
28 · median 51
Started
2023
with 1 other
No phase
8 of 19
none open now
Registered
19th of 19
by date

Among the 19 studies in Soft Tissue Injuries with a site in United States, this one is the 9th largest by enrollment of the 14 interventional ones that give a count, is one of 2 that started in 2023, is one of 8 with no phase, and was the 19th registered.

Soft Tissue Injuries

64 studies on the registry are indexed under Soft Tissue Injuries; 7 are open to participants now.

Browse Soft Tissue Injuries studies →

Open to participants now

1 of the 19 studies in Soft Tissue Injuries with a site in United States is open now. Recruiting first, the newest first:

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 2 Soft Tissue Injuries studies recruiting now, 1 sets no upper age limit and 1 stops at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Soft Tissue Injuries with a site in United States, or all of them as a file.
02

Study summary

This study will demonstrate the effectiveness of the NP-PWD therapy in managing complex wounds and improving wound healing parameters as compared to standard of care.

Read the detailed description

A study of 24 completed subjects will be conducted by enrolling patients who are requiring treatment for open skin and soft tissue defects. Patients will be screened for inclusion criteria and asked to consent to participate in the study. Following consent subjects will be randomized to receive treatment of one of the two study arms. Arm 1, the standard of care arm, will receive KCI Wound VAC Granulofoam. Arm 2, the study arm, will receive treatment with NP-PWD. Prior to the initial application, wound evaluations and photography will be completed to include assessment of infection with wound swabs. The wound dressing will be assessed for the need for change every 2-3 days and changed if clinically indicated (following each device IFU). Subjects will be followed for up to nine days post initial application. At minimum, the randomized treatment will be applied for 2 days after initial application for a subject to be considered completed. Subject who do not complete the treatment course (minimum of 2 days of treatment), may be replaced per investigators discretion. Follow up data will be gathered at each change/removal of the NP-PWD or Wound VAC. The data collected will include indications for dressing change, dressing change process, photographs and assessments for wound healing, infection, and adverse events. Gathered clinical data of the enrolled subjects will be used to evaluate the feasibility in using the NP-PWD device for wound healing management.

03

Conditions studied

  • Skin Wound
  • Soft Tissue Injuries

Browse trials for

Keywords

  • Negative pressure therapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

All subjects enrolled must meet ALL the following criteria:

  1. Patients 18 years of age or older of either gender
  2. Have an open skin or soft tissue defect requiring treatment

Exclusion criteria

Exclusion Criteria

Subjects who meet any of the following criteria will be excluded from the study:

  1. Active malignant disease at the study site
  2. Any concomitant medications or co-morbidities that, in the opinion of the investigator, may interfere with device use
  3. On any drug(s) or therapeutic device(s) to the study site in the last 30 days or any previous enrollment in this study
  4. Pregnant at enrollment
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
28 participants (actual)

Study arms

  • Experimental
    NP-PWD application

    Patients randomized to NP-PWD arm will have the NP-PWD device applied to their wound.

    Device: NP-PWD

  • Active comparator
    Standard of Care Wound VAC application

    Patients randomized to the standard of care arm will have the standard wound vac device applied to their wound.

    Device: Wound Vac

Interventions

  • DeviceNP-PWD

    Application of NP-PWD device.

  • DeviceWound Vac

    Application of wound vac device.

06

What researchers measure

Primary outcomes

  1. Feasibility and usability of device in treatment.

    The number and type of issues with the device will be documented to determine feasibility and usability. Events such as complications with application, device changes and early removal and rationale for events during the period the patient has the study device applied and throughout the entire enrollment period.

    Time frame: Seven to nine days post application.

Secondary outcomes

  1. Wound readiness for closure

    The treating physician will use their best medical judgment to assess the wound bed using rate of epithelization, signs of infection, exposed tendon or bone and overall appearance of the wound bed to determine the wounds readiness for closure. It will be documented the number of subjects from both groups that after treatment are ready to be grafted, or are no longer requiring surgery.

    Time frame: Seven to nine days post application.

  2. Incidence of colony forming units.

    Colony forming units are assessed by obtaining wound swabs and analysis of presence of colony forming units.

    Time frame: Seven to nine days post application.

  3. Ease of use of device by healthcare providers

    At each research visit the staff will be asked if they had any questions, concerns, complaints or comments about the device or dressing. There is not a separate healthcare provider questionnaire, but any information obtained will be placed in the comments section of the source documents and the feedback will be provided to manufacture.

    Time frame: Seven to nine days post application.

  4. Tolerability of the device by patient subjects

    Tolerability of device by subjects will be assessed by observation of the length of time subjects were able to keep the dressing on. The subject will be asked if they have any concern or complaints about the device or dressing. Their response and if applicable the reason for removal will all be documented.

    Time frame: Seven to nine days post application.

07

Study locations

1 site
  • Northeast Baptist
    San Antonio, Texas 78217, United States
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2023 to primary completion in Apr 2024, 8 months.

Of 18 interventional studies with no phase under Soft Tissue Injuries, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 15. This study's 8 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 1, 2024
First posted
Aug 14, 2024
StartActual
Aug 16, 2023
Primary completionActual
Apr 25, 2024
CompletionActual
Apr 25, 2024
Last update
Aug 14, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 14, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06552481
Lead sponsor
The Metis Foundation
Responsible party
Sponsor
First posted
Aug 14, 2024
Start date
Aug 16, 2023
Primary completion
Apr 25, 2024
Completion
Apr 25, 2024
Last update
Aug 14, 2024

Study contacts

Rodney Chan, MD
principal investigator · The Metis Foundation

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion